Indian Glioma therapeutics market size stood at around USD XX million in 2019 and is projected to reach USD XX million by 2028, exhibiting a CAGR of XX% during the forecast period.
The incidence of central nervous system (CNS) tumors in India ranges from 5 to 10 per 100,000 population with an increasing trend and accounts for 2% of malignancies. The development of a promising drug to treat Glioma has proved difficult to date, with many promising candidates failing to achieve the desired test results in the past few years. However, technological advancements in the diagnosis of gliomas and analysis of its progression through various imaging modalities have improved survival rates, thereby giving an enhanced edge for rapid evaluation of the efficacy of several pipeline drugs.
Market Driving Factors:
The driving factors in the growth of the Glioma therapeutics market include incurable status of the disease, increase in the aging population, and increasing prevalence of brain disorders. A person’s risk of developing Glioma depends on many factors, including age, genetics, and exposure to risk factors. Growth in the Glioma therapeutics market can also be attributed to patient’s constant contact with radiation and carcinogens. Furthermore, the late advent of disease symptoms leads to postponement in diagnosis and progression in the cancer stage, which results in the rising cost of the treatment.